Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study aims to predict deadly clots in liver patients

NCT ID NCT07422701

Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow about 2,500 adults with liver cirrhosis to learn who gets dangerous blood clots in the liver's main vein, how these clots affect survival, and whether blood-thinner medications are safe and helpful. Participants receive no experimental treatment—just routine care and checkups over two years. The goal is to give doctors better tools to predict and manage this complication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,522 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive adult patients with compensated or decompensated liver cirrhosis who are admitted to, or followed at, seven tertiary hospitals in China (Peking University First Hospital plus six regional centers). Both patients with imaging-confirmed portal vein thrombosis and those without PVT at baseline are eligible. The anticipated enrollment is 2 522 participants of either sex and all cirrhosis etiologies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Clinically or histologically confirmed liver cirrhosis (any etiology) * Contrast-enhanced abdominal ultrasound, CT, or MRI performed within 3 months before enrollment to document presence or absence of portal vein thrombosis (PVT) * Complete baseline clinical, laboratory, and imaging data available * Complete baseline clinical, laboratory, and imaging data available * Able and willing to provide written informed consent and comply with 24-month follow-up Exclusion Criteria: * Concomitant malignant tumor, including hepatocellular carcinoma * Previous transjugular intrahepatic portosystemic shunt (TIPS), splenectomy, or liver transplantation * Major surgery or severe trauma within 6 months prior to enrollment * Pregnancy or breastfeeding * Known hereditary thrombophilia or active systemic inflammatory disease * Inability or unwillingness to participate in scheduled follow-up (e.g., cognitive impairment, residence far from study sites)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis Portal vein thrombosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing YouAn Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Hengshui No. 3 People's Hospital

    Hengshui, Hebei, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Qingdao No.6 People's Hospital

    Qingdao, Shandong, China

  • Qinhuangdao No. 3 People's Hospital

    Qinhuangdao, Hebei, China

  • Shenzhen Third People's Hospital

    Shenzhen, Guangdong, China

  • Wuxi No.5 People's Hospital

    Wuxi, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.